The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: No evidence for other ovarian cancer-susceptibility genes

American Journal of Human Genetics

Volumn 65, Issue 4, 1999, Pages 1021-1029

  Gayther, Simon A ^a   Russell, Paul ^a   Harrington, Patricia ^a   Antoniou, Antonis C ^a   Easton, Douglas F ^a   Ponder, Bruce A J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL;

EID: 0033365227     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/302583     Document Type: Article

References (36)

1. Chapman MS, Verma IM (1996) Transcriptional activation by BRCA1. Nature 382:678-679
2. Chen PL, Chen CF, Chen Y, Xiao J, Sharp ZD, Lee WH (1998) The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. Proc Natl Acad Sci USA 95:5287-5292
3. Claus EB, Risch N, Thompson WD (1991) Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study. Am J Hum Genet 48:232-242
4. Easton D (1997) Breast cancer genes - what are the real risks? Nat Genet 16:210-211
5. Easton DF, Bishop DT, Ford D, Crockford GP (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 52:678-701
6. Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457-1462
7. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62:676-689
8. Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, Ponder BA, et al (1997) Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 60:313-319
9. Gayther SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF, Ponder BA (1997a) Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet 60:1239-1242
10. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA, Stratton MR, et al (1997b) Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 15:103-105
11. Gayther SA, Ponder BA (1998) Clues to the function of the tumour susceptibility gene BRCA2. Dis Markers 14:1-8
12. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, et al (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11:428-433
13. Lange K, Weeks D, Boehnke M (1988) Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol 5:471-472
14. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, et al (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215-1225
15. Lynch HT, Albano WA, Lynch JF, Lynch PM, Campbell A (1982) Surveillance and management of patients at high genetic risk for ovarian carcinoma. Obstet Gynecol 59:589-596
16. Miki Y, Swensen J, Schattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, et al (1994) A strong candidate for the breast and ovarian-cancer susceptibility gene BRCA1. Science 266:66-71
17. Narod SA, Ford D, Devilee P, Barkardottir RB, Lynch HT, Smith SA, Ponder BA, et al (1995) An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 56:254-264
18. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, et al (1996a) Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 13:126-128
19. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, Tomlinson G, et al (1996b) Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 58:271-280
20. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, Haseltine WA, et al (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263:1625-1629
21. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, Hogervorst FB, et al (1997) BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17:341-345
22. Pharoah PD, Easton DF, Stockton DL, Gayther SA, Ponder BA (1999) Survival in familial, BRCA1 and BRCA2 associated epithelial ovarian cancer. Cancer Res 59:868-871
23. Puget N, Sinilnikova OM, Stoppa-Lyonnet D, Audoynaud C, Pages S, Lynch HT, Goldgar D, et al (1999) An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation? Am J Hum Genet 64:300-302
24. Puget N, Torchard D, Serova-Sinilnikova OM, Lynch HT, Feunteun J, Lenoir GM, Mazoyer S (1997) A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res 57:828-831
25. Ramus SJ, Kote-Jarai Z, Friedman LS, van der Looij M, Gayther SA, Csokay B, Ponder BA, et al (1997) Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet 60:1242-1246
26. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteum J, Ashley T, et al (1997) Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 8:265-275
27. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, et al (1995) A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic resting and screening. JAMA 273:535-541
28. Steichen-Gersdorf E, Gallion HH, Ford D, Girodet C, Easton D, DiCioccio RA, Evans G, et al (1994) Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet 55:870-875
29. Stratton JF, Pharoah PD, Smith SK, Easton D, Ponder BA (1998) A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol 105:493-499
30. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11:198-200
31. Swensen J, Hoffman M, Skolnick MH, Neuhausen SL (1997) Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family. Hum Mol Genet 6:1513-1517
32. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, et al (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12:333-337
33. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, et al (1996) A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet 13:117-119
34. Wong AKC, Pero R, Ormonde PA, Tavtigian SV, Bartel PL (1997) RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene BRCA2. J Biol Chem 272:31941-31944
35. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792
36. Zhang H, Tombline G, Weber BL (1998) BRCA1, BRCA2, and DNA damage response: collision or collusion? Cell 92 :433-436